Ovarian cancer presents at an advanced stage in more than 75% of patients. Early detection has great promise to improve clinical outcomes. Although the advancing proteomic technologies led to the discovery of numerous ovarian cancer biomarkers, no screening method has been recommended for early detection of ovarian cancer. Complexity and heterogeneity of ovarian carcinogenesis is a major obstacle to discover biomarkers. As cancer arises due to accumulation of genetic change, understanding the close connection between genetic changes and ovarian carcinogenesis would provide the opportunity to find novel gene-level ovarian cancer biomarkers. In this review, we summarize the various gene-based biomarkers by genomic technologies, including inherited gene mutations, epigenetic changes, and differential gene expression. In addition, we suggest the strategy to discover novel gene-based biomarkers with recently introduced next generation sequencing. (J Cancer Prev 2013;18:298-312) 
INTRODUCTION
Ovarian cancer is the leading cause of mortality from female reproductive cancer. Although it is the ninth most common cancer, it is among the five leading causes of cancer death in women. 1 No definite symptoms related with early-stage disease and no effective screening methods make its early detection difficult, which results in about two-third patients with advanced-stage ovarian cancer at the diagnosis. 2 When we consider that 5-year survival rate is up to 90% in patients with early-stage ovarian cancer while it is less than 20% in those with advanced-stage disease, the development of effective screening tests and their applications in clinical setting are very important to improve the prognosis of ovarian cancer by early detection. 3 Cancers are caused by the accumulation of genetic damages, but the genetic mutations and pathways for early ovarian carcinogenesis are largely unknown. Considering the close relationship between genetic alterations and ovarian carcinogenesis, the research on gene level may be expected to provide novel ovarian cancer biomarkers. 4 With application of second-generation DNA sequencing technologies, it has become feasible to fully sequence whole genome more fast and less cost than traditional ones. The focus of this review is on ovarian cancer with challenges of its early detection and how recent development of genomic technologies could contribute to overcoming these challenges.
OVARIAN CANCER AND CHALLENGES IN ITS EARLY DETECTION
Ovarian cancer is relatively a rare disease with an incidence of less than 40 per 100,000 per year. 1 Thus, the ideal screening method has high specificity to avoid unnecessary surgery-related complications, and high positive predictive value to detect early-stage ovarian cancer which can be treated by optimal debulking surgery with adjuvant chemotherapy. Considering the low incidence of ovarian cancer, most of researchers agree that a screening test should satisfy sensitivity of ＞75%, specificity of ＞ 99.6% and positive predictive value of ＞10%.
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Several biomarkers have been developed as feasible tools for the early detection and follow-up of ovarian cancer. In particular, CA-125, the most widely used serum biomarker for ovarian cancer, has a value for monitoring tumor response and disease recurrence after treatment. 5 Approximately 80% of patients with advanced-stage ovarian cancer show elevated serum CA-125 levels; more than 50% of those with early-stage disease demonstrate normal values. 8 Moreover, it has high false-positive rate of 30%,
showing elevated levels in benign conditions including pregnancy, pelvic inflammatory disease and endometriosis. 9 To overcome these limitations of serum CA- 125 closely associated with the fallopian tube rather than ovarian surface epithelium. 35 Although several evidences supports for fallopian tube as the origin of ovarian cancer, further studies and more samples are needed to approve STIC as a precursor lesion for high grade serous carcinoma.
Efforts to understand the pathogenesis of ovarian cancer should be performed to discover novel ovarian cancer biomarkers.
GENE-BASED APPROACHES TO DIAGNOSIS OF OVARIAN CANCER
Since sequencing the entire human genome was achieved (Table 1 ).
Inherited gene mutations
It is currently accepted that at least 10% of all epithelial and BRCA2 genes are large tumor suppressor gene located on chromosome 17q21 and 13q12-13, respectively. 40, 41 Previous studies showed that both BRCA proteins participate in multiple functions, such as DNA repair, transcriptional regulation of gene expression, and cell cycle. 42 More than 250 mutations may occur in both BRCA genes.
Main mutations are frameshift or nonsense variety, accounting for 80% of BRCA gene mutations. 39 These mutations affect the creation of stop codons and protein truncations.
In U.S., Myriad Genetics has gene patents and therefore only company to offer clinical testing for BRCA1 and BRCA2. 43 The company offers standard test which includes sequencing of all the coding exons, intron-exon boun- predictive biomarkers in ovarian cancer will be discovered.
The major challenge of whole genomic sequencing is computational, biological and clinical analyses of the genomic data. The computational analyses will assess reproducibility and statistical significance, the biological analyses will evaluate the association between pathways and functional relevance of mutated genes to cancer, and the clinical analyses will the effect of genome on incidence, histology, prognosis, and therapeutic response. 87 In addi- 122 Therefore, type II tumor should be targeted for screening. Until recently, a major limitation to studying ovarian cancer progression has been the lack of tissue for study. This is because almost type II ovarian cancers are not confined to ovary, even at their inception.
Only 0.5% of type II tumors were confined to the ovary from the British Columbia Tumor Registry. 123 As fallopian tube carcinoma was included as part of disease spectrum associated with hereditary BRCA mutations, tubal intraepithelial carcinoma has been suggested as the possible precursor lesion for type II tumors. 124 We suggest the strategy to discover novel gene-based biomarkers in ovarian cancer, especially for high-grade serous carcinoma, the prototype of type II tumors (Fig. 1) . First, much samples associated with precancerous lesion such as STIC are required through collaboration. And then, mutations in- 
